Page 15 - Cipla

Stocks to Watch: Bajaj Auto, Axis Bank, ITC, Maruti, L&T, SBI Life, Cipla

The broader markets may swing to the global cues, while individual stocks are likely to react to corporate earnings and company specific developments in trade today

Cipla posts 7% year-on-year rise in Q2 PAT, riding on 10% revenue growth

Sequentially, however, the company has posted muted growth-revenue growth of 0.3%, and a PAT decline of 0.5%. Ebitda dipped sequentially too, by 9%

Cipla to sell Eli Lilly's insulin products Humalog, Trulicity in India

Only 3 firms - Novo Nordisk, Sanofi, and Eli Lilly - supply insulin to patients in the US. These three companies, commonly called the 'Big Three', control over 90 per cent of the global insulin market

Cipla eyes acquisitions in India, US after Covid-led windfall

With a funding frenzy currently underway in India, Cipla may struggle to find attractive targets

Hold Nifty long with a stop at Tuesday's low, recommends Vinay Rajani

On the upside, the Nifty may face resistance in the range of 17,950-18,000, says the technical analyst from HDFC Securities

India growth, steady margins are key to near-term upsides for Cipla

Over the medium term, success of the new launches in the US would drive gains

Stocks to watch: M&M, Glenmark Life Sciences, Cipla, Adani Power, Tata Chem

Stocks from the banking, real estate and auto sectors will be in focus amid the RBI policy outcome later today

Cipla's Q1 PAT grows 24% to Rs 715 crore riding on domestic sales

The company posted a 27% YoY increase in income from operations, at Rs 5,504 cr. Ebitda grew 28% to Rs 1,346 cr with a resulting Ebitda margin of 24.5%

Top headlines: Govt buries retro tax; Cipla Q1 net profit rises 24%

Business Standard brings you the top headlines on Thursday

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Cipla, Dr Reddy's Labs: Tech charts show up to 11% upside in pharma stocks

After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100

Cipla hits new high on DCGI nod to import Moderna vaccine; up 4% in 2 days

At this stage, there is no definitive agreement on commercial supplies, the company said in response to media queries on vaccine import

Stocks to watch: Voda Idea, RIL, Cipla, Indiabulls Housing, pharma stocks

Vodafone Idea is likely to post a narrowing of losses in Q4FY21 even though subscriber losses and zero IUC regime may dent the top-line

Top headlines: Amazon battles regulators, e-way bill generation grows

Business Standard brings you the top headlines on Wednesday

Cipla gets DCGI nod to import Moderna vaccine; no commercial deal yet

1st mRNA vax part of US-India pact; no commercial deal yet

Five Indian drugmakers to jointly start trial of Merck & Co's Covid-19 drug

(Reuters) - Five Indian generic drugmakers, including Cipla and Dr Reddy's Laboratories, said on Tuesday they would jointly conduct a clinical trial of Merck & Co's anti-viral drug to treat mild COVID-19 in non-hospitalised patients in India.

Nifty headed for upside target of 16,000: Vinay Rajani of HDFC Securities

Momentum indicators are in favour of bulls

Seeking clarity, guidance from govt for Covid vaccine import: Cipla

Pharma major Cipla on Tuesday said it is seeking clarity and guidance from the government on the possible roadmap to import vaccine, while stressing that it has been at the forefront of Covid-19 care

Cipla says close to committing $1 billion to Moderna for booster vaccine

The company has further requested for the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals

Pfizer ready with 50 mn doses for India; Moderna jab likely in 2022: Report

Moderna is expecting to launch a single-dose COVID-19 vaccine in India next year and is in talks with Cipla among other Indian firms, while another US giant Pfizer is ready to offer 5 crore shots in 2021 itself but it wants significant regulatory relaxations including indemnification, sources said on Tuesday. While Moderna has conveyed to Indian authorities that it does not have surplus vaccines to share in 2021, there are limited prospects of Johnson & Johnson exporting its jabs from the US to other countries in the near future, the sources privy to discussions added. Two rounds of high-level meetings chaired by the Cabinet Secretary were held last week on the availability of vaccines in the global as well as domestic markets as it was felt that there is an urgent need to procure the jabs at a time the country is reeling under an unprecedented second wave of COVID-19 and a widening gap between supply and requirement. Currently, the country is using two 'made-in India' jabs -- ...